Source disclosure: January 20, 2026
Takeda Pharmaceutical Company Limited [4502.T]
TOKYO, Jan 20 (Pulse News Wire) – Takeda Pharmaceutical Company Limited (4502.T) revised its phase 3 trial data for Zasocitinib, showing significant improvements in skin lesions for patients with moderate-to-severe plaque psoriasis. The study demonstrated superiority over placebo in two primary endpoints, achieving PASI 75 scores significantly higher from week four onwards.
By week 24, half of the patients achieved PASI 90, while approximately 40% reached complete clearance (PASI 100). CEO Christophe Weber stated, “These results support Zasocitinib’s potential as a major oral treatment option for psoriasis patients, offering rapid efficacy and safety.” The company plans to file for regulatory approval with the FDA and other authorities in fiscal 2026.
Zasocitinib is currently being evaluated in additional trials, including direct comparisons with Deucravacitinib and studies for psoriatic arthritis, Crohn’s disease, ulcerative colitis, and vitiligo. The impact on fiscal 2025 earnings forecasts remains minor.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing